Trial Outcomes & Findings for A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults (NCT NCT01427309)

NCT ID: NCT01427309

Last Updated: 2015-04-20

Results Overview

Influenza positive cultures were confirmed using direct immunofluorescence techniques with influenza type-specific antibodies. 3 culture methods were utilized for each NP sample (Classic Flu A and B culture using Madin Darby Canine Kidney cells, Classic Flu A and B culture using Rhesus Monkey Kidney cells, and R Mix Flu A and B culture). The initial molecular test (PCR) was the validated ProFlu+™ assay by Prodesse, Inc., Waukesha, WI, which had been approved by the Food and Drug Administration through a 510K evaluation for specific detection of Influenza A, B or Respiratory Syncytial Virus. A protocol-defined influenza-like illness was determined by the occurrence of at least 1 of the following respiratory symptoms: sore throat, cough, sputum production, wheezing, or difficulty breathing; concurrently with at least one of the following systemic symptoms: fever (defined as temperature \> 99.0°F \[\> 37.2°C\]), chills (shivering), tiredness (fatigue), headache, or myalgia (muscle aches).

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

31989 participants

Primary outcome timeframe

≥14 days post-vaccination

Results posted on

2015-04-20

Participant Flow

The study participants were enrolled from 06 September through 09 October 2011 for Year 1; and 09 through 21 October 2012 for Year 2 at 126 sites in the United States and Canada.

A total of 31,989 participants were enrolled 31,983 were randomized and vaccinated in this study.

Participant milestones

Participant milestones
Measure	Fluzone® High Dose Vaccine (Year 1) Adults ≥65 years of age received one dose of Fluzone High Dose vaccine	Fluzone® Vaccine (Year 1) Adults ≥65 years of age received one dose of Fluzone vaccine	Fluzone® High Dose Vaccine (Year 2) Adults ≥65 years of age received one dose of Fluzone High Dose vaccine	Fluzone® Vaccine (Year 2) Adults ≥65 years of age received one dose of Fluzone vaccine
Overall Study STARTED	7253	7244	8737	8749
Overall Study COMPLETED	6881	6837	8376	8373
Overall Study NOT COMPLETED	372	407	361	376

Reasons for withdrawal

Reasons for withdrawal
Measure	Fluzone® High Dose Vaccine (Year 1) Adults ≥65 years of age received one dose of Fluzone High Dose vaccine	Fluzone® Vaccine (Year 1) Adults ≥65 years of age received one dose of Fluzone vaccine	Fluzone® High Dose Vaccine (Year 2) Adults ≥65 years of age received one dose of Fluzone High Dose vaccine	Fluzone® Vaccine (Year 2) Adults ≥65 years of age received one dose of Fluzone vaccine
Overall Study Lost to Follow-up	130	145	122	135
Overall Study Protocol Violation	42	69	125	124
Overall Study Adverse Event	0	0	3	1
Overall Study Serious adverse event	52	45	50	61
Overall Study Withdrawal by Subject	148	148	61	55

Baseline Characteristics

A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Fluzone® High Dose Vaccine (Year 1) n=7253 Participants Adults ≥65 years of age received one dose of Fluzone High Dose vaccine	Fluzone® Vaccine (Year 1) n=7244 Participants Adults ≥65 years of age received one dose of Fluzone vaccine	Fluzone® High Dose Vaccine (Year 2) n=8737 Participants Adults ≥65 years of age received one dose of Fluzone High Dose vaccine	Fluzone® Vaccine (Year 2) n=8749 Participants Adults ≥65 years of age received one dose of Fluzone vaccine	Total n=31983 Participants Total of all reporting groups
Age, Categorical <=18 years	0 Participants n=99 Participants	0 Participants n=107 Participants	0 Participants n=206 Participants	0 Participants n=7 Participants	0 Participants n=31 Participants
Age, Categorical Between 18 and 65 years	0 Participants n=99 Participants	0 Participants n=107 Participants	0 Participants n=206 Participants	0 Participants n=7 Participants	0 Participants n=31 Participants
Age, Categorical >=65 years	7253 Participants n=99 Participants	7244 Participants n=107 Participants	8737 Participants n=206 Participants	8749 Participants n=7 Participants	31983 Participants n=31 Participants
Age, Continuous	73.3 Years STANDARD_DEVIATION 5.88 • n=99 Participants	73.2 Years STANDARD_DEVIATION 5.82 • n=107 Participants	73.3 Years STANDARD_DEVIATION 5.74 • n=206 Participants	73.4 Years STANDARD_DEVIATION 5.85 • n=7 Participants	73.3 Years STANDARD_DEVIATION 5.82 • n=31 Participants
Sex: Female, Male Female	4085 Participants n=99 Participants	4041 Participants n=107 Participants	5046 Participants n=206 Participants	4922 Participants n=7 Participants	18094 Participants n=31 Participants
Sex: Female, Male Male	3168 Participants n=99 Participants	3203 Participants n=107 Participants	3691 Participants n=206 Participants	3827 Participants n=7 Participants	13889 Participants n=31 Participants
Region of Enrollment United States	6953 Participants n=99 Participants	6944 Participants n=107 Participants	8315 Participants n=206 Participants	8326 Participants n=7 Participants	30538 Participants n=31 Participants
Region of Enrollment Canada	300 Participants n=99 Participants	300 Participants n=107 Participants	422 Participants n=206 Participants	423 Participants n=7 Participants	1445 Participants n=31 Participants

PRIMARY outcome

Timeframe: ≥14 days post-vaccination

Population: Clinical efficacy was assessed in subjects who met all eligibility criteria, received the vaccine they were randomized to, had successful surveillance contact, did not received additional influenza vaccinations and did not have protocol deviations likely to impact their responses for the primary and secondary endpoints (Per-protocol analysis set).

Influenza positive cultures were confirmed using direct immunofluorescence techniques with influenza type-specific antibodies. 3 culture methods were utilized for each NP sample (Classic Flu A and B culture using Madin Darby Canine Kidney cells, Classic Flu A and B culture using Rhesus Monkey Kidney cells, and R Mix Flu A and B culture). The initial molecular test (PCR) was the validated ProFlu+™ assay by Prodesse, Inc., Waukesha, WI, which had been approved by the Food and Drug Administration through a 510K evaluation for specific detection of Influenza A, B or Respiratory Syncytial Virus. A protocol-defined influenza-like illness was determined by the occurrence of at least 1 of the following respiratory symptoms: sore throat, cough, sputum production, wheezing, or difficulty breathing; concurrently with at least one of the following systemic symptoms: fever (defined as temperature \> 99.0°F \[\> 37.2°C\]), chills (shivering), tiredness (fatigue), headache, or myalgia (muscle aches).

Outcome measures

Outcome measures
Measure	Fluzone® High Dose Vaccine (Year 1) n=7209 Participants Adults ≥65 years of age received one dose of Fluzone High Dose vaccine	Fluzone® Vaccine (Year 1) n=7207 Participants Adults ≥65 years of age received one dose of Fluzone vaccine	Fluzone® High Dose Vaccine (Year 2) n=8683 Participants Adults ≥65 years of age received one dose of Fluzone High Dose vaccine	Fluzone® Vaccine (Year 2) n=8704 Participants Adults ≥65 years of age received one dose of Fluzone vaccine
Occurrences of Culture- or Polymerase Chain Reaction (PCR)-Confirmed Influenza Caused by Any Influenza Viral Types/Subtypes, in Association With a Protocol-defined Influenza-like Illness (ILI).	23 Participants	42 Participants Interval 0.0 to 0.0	204 Participants Interval 0.0 to 0.0	258 Participants Interval 0.0 to 0.0

SECONDARY outcome

Timeframe: ≥14 days post-vaccination

Population: Clinical efficacy was assessed in subjects who met all eligibility criteria, received the vaccine they were randomized to, had successful surveillance contact, did not received additional influenza vaccinations and did not have protocol deviations likely to impact their responses for the primary and secondary endpoints (Per-protocol analysis set).

Influenza positive cultures were confirmed by using direct immunofluorescence techniques with influenza type-specific (i.e., for Influenza A and Influenza B) antibodies. For culture confirmation of influenza, 3 different culture methods were utilized for each NP sample (Classic Flu A and B culture using Madin Darby Canine Kidney \[MDCK\] cells, Classic Flu A and B culture using Rhesus Monkey Kidney \[RhMK\] cells, and R Mix Flu A and B culture. For antigenic similarity determinations, a standard hemagglutination inhibition test using a panel of ferret antisera (ferret antigenicity testing) was used.

Outcome measures

Outcome measures
Measure	Fluzone® High Dose Vaccine (Year 1) n=7209 Participants Adults ≥65 years of age received one dose of Fluzone High Dose vaccine	Fluzone® Vaccine (Year 1) n=7207 Participants Adults ≥65 years of age received one dose of Fluzone vaccine	Fluzone® High Dose Vaccine (Year 2) n=8683 Participants Adults ≥65 years of age received one dose of Fluzone High Dose vaccine	Fluzone® Vaccine (Year 2) n=8704 Participants Adults ≥65 years of age received one dose of Fluzone vaccine
Occurrences of Culture-confirmed Influenza Caused by Influenza Viral Types/Subtypes That Are Antigenically Similar to Those Contained in the Vaccine Formulations, in Association With a Protocol-defined Influenza-like Illness (ILI)	2 Participants	7 Participants Interval 0.0 to 0.0	61 Participants Interval 0.0 to 0.0	85 Participants Interval 0.0 to 0.0

SECONDARY outcome

Timeframe: ≥14 days post-vaccination

Population: Occurrences of culture-confirmed influenza caused by any influenza viral types/subtypes, in association with a protocol-defined influenza-like illness was assessed in the Per-Protocol Analysis Set.

For culture confirmation of influenza, 3 different culture methods were utilized for each NP sample (Classic Flu A and B culture using Madin Darby Canine Kidney \[MDCK\] cells, Classic Flu A and B culture using Rhesus Monkey Kidney \[RhMK\] cells, and R Mix Flu A and B culture). A protocol-defined influenza-like illness (ILI) was determined by the occurrence of at least one of the following respiratory symptoms: sore throat, cough, sputum production, wheezing, or difficulty breathing; concurrently with at least one of the following systemic symptoms: fever (defined as temperature \> 99.0°F \[\> 37.2°C\]), chills (shivering), tiredness (fatigue), headache, or myalgia (muscle aches).

Outcome measures

Outcome measures
Measure	Fluzone® High Dose Vaccine (Year 1) n=7209 Participants Adults ≥65 years of age received one dose of Fluzone High Dose vaccine	Fluzone® Vaccine (Year 1) n=7207 Participants Adults ≥65 years of age received one dose of Fluzone vaccine	Fluzone® High Dose Vaccine (Year 2) n=8683 Participants Adults ≥65 years of age received one dose of Fluzone High Dose vaccine	Fluzone® Vaccine (Year 2) n=8704 Participants Adults ≥65 years of age received one dose of Fluzone vaccine
Occurrences of Culture-confirmed Influenza Caused by Any Influenza Viral Types/Subtypes, in Association With a Protocol-defined Influenza-like Illness	20 Participants	33 Participants Interval 0.0 to 0.0	185 Participants Interval 0.0 to 0.0	234 Participants Interval 0.0 to 0.0

SECONDARY outcome

Timeframe: ≥14 days post-vaccination

Population: Occurrences of culture-confirmed influenza caused by influenza viral types/subtypes that are antigenically similar to those contained in the vaccine formulations, in association with a modified CDC-defined influenza-like illness were assessed in the Per-Protocol Analysis Set.

Influenza positive cultures were confirmed by using direct immunofluorescence techniques with influenza type-specific antibodies. For culture confirmation of influenza, 3 different culture methods were utilized for each NP sample (Classic Flu A and B culture using Madin Darby Canine Kidney cells, Classic Flu A and B culture using Rhesus Monkey Kidney cells, and R Mix Flu A and B culture). For antigenic similarity determinations, a standard hemagglutination inhibition test using a panel of ferret antisera (ferret antigenicity testing) was used. The modified Centers for Disease Control and Prevention-defined influenza-like illness is the occurrence of fever (defined as temperature \> 99.0°F \[\> 37.2°C\]) with cough or sore throat.

Outcome measures

Outcome measures
Measure	Fluzone® High Dose Vaccine (Year 1) n=7209 Participants Adults ≥65 years of age received one dose of Fluzone High Dose vaccine	Fluzone® Vaccine (Year 1) n=7207 Participants Adults ≥65 years of age received one dose of Fluzone vaccine	Fluzone® High Dose Vaccine (Year 2) n=8683 Participants Adults ≥65 years of age received one dose of Fluzone High Dose vaccine	Fluzone® Vaccine (Year 2) n=8704 Participants Adults ≥65 years of age received one dose of Fluzone vaccine
Occurrences of Culture-confirmed Influenza Caused by Influenza Viral Types/Subtypes That Are Antigenically Similar to Those Contained in the Vaccine Formulations, in Association With a Modified CDC-defined Influenza-like Illness.	0 Participants	3 Participants Interval 0.0 to 0.0	22 Participants Interval 0.0 to 0.0	42 Participants Interval 0.0 to 0.0

SECONDARY outcome

Timeframe: ≥14 days post-vaccination

Population: Occurrences of culture-confirmed influenza caused by any influenza viral types/subtypes, in association with a modified CDC-defined influenza-like illness were assessed in the Per-Protocol Analysis Set.

Influenza positive cultures were confirmed by using direct immunofluorescence techniques with influenza type-specific antibodies. For culture confirmation of influenza, 3 different culture methods were utilized for each NP sample (Classic Flu A and B culture using Madin Darby Canine Kidney cells, Classic Flu A and B culture using Rhesus Monkey Kidney cells, and R Mix Flu A and B culture). For antigenic similarity determinations, a standard hemagglutination inhibition test using a panel of ferret antisera (ferret antigenicity testing) was used. The modified Centers for Disease Control and Prevention-defined influenza-like illness is the occurrence of fever (defined as temperature \> 99.0°F \[\> 37.2°C\]) with cough or sore throat.

Outcome measures

Outcome measures
Measure	Fluzone® High Dose Vaccine (Year 1) n=7209 Participants Adults ≥65 years of age received one dose of Fluzone High Dose vaccine	Fluzone® Vaccine (Year 1) n=7207 Participants Adults ≥65 years of age received one dose of Fluzone vaccine	Fluzone® High Dose Vaccine (Year 2) n=8683 Participants Adults ≥65 years of age received one dose of Fluzone High Dose vaccine	Fluzone® Vaccine (Year 2) n=8704 Participants Adults ≥65 years of age received one dose of Fluzone vaccine
Occurrences of Culture-confirmed Influenza Caused by Any Influenza Viral Types/Subtypes, in Association With a Modified CDC-defined Influenza-like Illness	7 Participants	7 Participants Interval 0.0 to 0.0	77 Participants Interval 0.0 to 0.0	103 Participants Interval 0.0 to 0.0

SECONDARY outcome

Timeframe: ≥14 days post-vaccination

Population: Occurrences of culture-confirmed influenza caused by influenza viral types/subtypes that are antigenically similar to those contained in the vaccine formulations, in association with a respiratory illness were assessed in the Per-Protocol Analysis Set.

Influenza positive cultures were confirmed by using direct immunofluorescence techniques with influenza type-specific antibodies. For culture confirmation of influenza, 3 different culture methods were utilized for each NP sample (Classic Flu A and B culture using Madin Darby Canine Kidney cells, Classic Flu A and B culture using Rhesus Monkey Kidney cells, and R Mix Flu A and B culture). For antigenic similarity determinations, a standard hemagglutination inhibition test using a panel of ferret antisera (ferret antigenicity testing) was used. Respiratory illness was defined as the occurrence of a new onset (or exacerbation of a pre-existing condition/symptom) of one or more of the following symptoms (that persist for or reoccur after a period of at least 12 hours): sneezing, stuffy or runny nose (nasal congestion), sore throat, cough, sputum production, wheezing, or difficulty breathing.

Outcome measures

Outcome measures
Measure	Fluzone® High Dose Vaccine (Year 1) n=7209 Participants Adults ≥65 years of age received one dose of Fluzone High Dose vaccine	Fluzone® Vaccine (Year 1) n=7207 Participants Adults ≥65 years of age received one dose of Fluzone vaccine	Fluzone® High Dose Vaccine (Year 2) n=8683 Participants Adults ≥65 years of age received one dose of Fluzone High Dose vaccine	Fluzone® Vaccine (Year 2) n=8704 Participants Adults ≥65 years of age received one dose of Fluzone vaccine
Occurrences of Culture-confirmed Influenza Caused by Influenza Viral Types/Subtypes That Are Antigenically Similar to Those Contained in the Vaccine Formulations, in Association With a Respiratory Illness	7 Participants	9 Participants Interval 0.0 to 0.0	78 Participants Interval 0.0 to 0.0	109 Participants Interval 0.0 to 0.0

SECONDARY outcome

Timeframe: ≥14 days post-vaccination

Population: Occurrences of culture-confirmed influenza caused by any influenza viral types/subtypes, in association with a respiratory illness were assessed in the Per-Protocol Analysis Set.

Influenza positive cultures were confirmed by using direct immunofluorescence techniques with influenza type-specific (i.e., for Influenza A and Influenza B) antibodies. For culture confirmation of influenza, 3 different culture methods were utilized for each NP sample (Classic Flu A and B culture using Madin Darby Canine Kidney cells, Classic Flu A and B culture using Rhesus Monkey Kidney cells, and R Mix Flu A and B culture). Respiratory illness is defined as the occurrence of a new onset (or exacerbation of a pre-existing condition/symptom) of one or more of the following symptoms (that persist for or reoccur after a period of at least 12 hours): sneezing, stuffy or runny nose (nasal congestion), sore throat, cough, sputum production, wheezing, or difficulty breathing.

Outcome measures

Outcome measures
Measure	Fluzone® High Dose Vaccine (Year 1) n=7209 Participants Adults ≥65 years of age received one dose of Fluzone High Dose vaccine	Fluzone® Vaccine (Year 1) n=7207 Participants Adults ≥65 years of age received one dose of Fluzone vaccine	Fluzone® High Dose Vaccine (Year 2) n=8683 Participants Adults ≥65 years of age received one dose of Fluzone High Dose vaccine	Fluzone® Vaccine (Year 2) n=8704 Participants Adults ≥65 years of age received one dose of Fluzone vaccine
Occurrences of Culture-confirmed Influenza Caused by Any Influenza Viral Types/Subtypes, in Association With a Respiratory Illness	38 Participants	44 Participants Interval 0.0 to 0.0	238 Participants Interval 0.0 to 0.0	294 Participants Interval 0.0 to 0.0

OTHER_PRE_SPECIFIED outcome

Timeframe: Day 0 up to Day 240 post-vaccination

Population: Safety was assessed in the Full Analysis Set.

All serious adverse events, including deaths and adverse events (AEs) of special interest (Guillain Barre Syndrome, Bell's Palsy, encephalitis/myelitis, optic neuritis, Stevens Johnson Syndrome, and toxic epidermal necrolysis) were collected.

Outcome measures

Outcome measures
Measure	Fluzone® High Dose Vaccine (Year 1) n=7254 Participants Adults ≥65 years of age received one dose of Fluzone High Dose vaccine	Fluzone® Vaccine (Year 1) n=7243 Participants Adults ≥65 years of age received one dose of Fluzone vaccine	Fluzone® High Dose Vaccine (Year 2) n=8738 Participants Adults ≥65 years of age received one dose of Fluzone High Dose vaccine	Fluzone® Vaccine (Year 2) n=8748 Participants Adults ≥65 years of age received one dose of Fluzone vaccine
Safety Overview After Injection With Either Fluzone High Dose or Fluzone Vaccine Through the End of Surveillance Period Adverse events of special interest	2 Participants	2 Participants Interval 0.0 to 0.0	1 Participants Interval 0.0 to 0.0	4 Participants Interval 0.0 to 0.0
Safety Overview After Injection With Either Fluzone High Dose or Fluzone Vaccine Through the End of Surveillance Period Guillain Barré Syndrome	0 Participants	0 Participants Interval 0.0 to 0.0	0 Participants Interval 0.0 to 0.0	1 Participants Interval 0.0 to 0.0
Safety Overview After Injection With Either Fluzone High Dose or Fluzone Vaccine Through the End of Surveillance Period Bell's palsy	0 Participants	2 Participants Interval 0.0 to 0.0	1 Participants Interval 0.0 to 0.0	3 Participants Interval 0.0 to 0.0
Safety Overview After Injection With Either Fluzone High Dose or Fluzone Vaccine Through the End of Surveillance Period Encephalitis/myelitis	1 Participants	0 Participants Interval 0.0 to 0.0	0 Participants Interval 0.0 to 0.0	0 Participants Interval 0.0 to 0.0
Safety Overview After Injection With Either Fluzone High Dose or Fluzone Vaccine Through the End of Surveillance Period Optic neuritis	0 Participants	0 Participants Interval 0.0 to 0.0	0 Participants Interval 0.0 to 0.0	0 Participants Interval 0.0 to 0.0
Safety Overview After Injection With Either Fluzone High Dose or Fluzone Vaccine Through the End of Surveillance Period Serious adverse events (SAE)	680 Participants	704 Participants Interval 0.0 to 0.0	643 Participants Interval 0.0 to 0.0	738 Participants Interval 0.0 to 0.0
Safety Overview After Injection With Either Fluzone High Dose or Fluzone Vaccine Through the End of Surveillance Period Stevens Johnson syndrome	1 Participants	0 Participants Interval 0.0 to 0.0	0 Participants Interval 0.0 to 0.0	0 Participants Interval 0.0 to 0.0
Safety Overview After Injection With Either Fluzone High Dose or Fluzone Vaccine Through the End of Surveillance Period Toxic epidermal necrolysis	0 Participants	0 Participants Interval 0.0 to 0.0	0 Participants Interval 0.0 to 0.0	0 Participants Interval 0.0 to 0.0
Safety Overview After Injection With Either Fluzone High Dose or Fluzone Vaccine Through the End of Surveillance Period Related SAE	1 Participants	0 Participants Interval 0.0 to 0.0	2 Participants Interval 0.0 to 0.0	0 Participants Interval 0.0 to 0.0
Safety Overview After Injection With Either Fluzone High Dose or Fluzone Vaccine Through the End of Surveillance Period Related SAE leading to study discontinuation	0 Participants	0 Participants Interval 0.0 to 0.0	0 Participants Interval 0.0 to 0.0	0 Participants Interval 0.0 to 0.0
Safety Overview After Injection With Either Fluzone High Dose or Fluzone Vaccine Through the End of Surveillance Period Death	48 Participants	40 Participants Interval 0.0 to 0.0	35 Participants Interval 0.0 to 0.0	44 Participants Interval 0.0 to 0.0
Safety Overview After Injection With Either Fluzone High Dose or Fluzone Vaccine Through the End of Surveillance Period SAE leading to study discontinuation	52 Participants	45 Participants Interval 0.0 to 0.0	47 Participants Interval 0.0 to 0.0	58 Participants Interval 0.0 to 0.0

Adverse Events

Fluzone® High Dose Vaccine (Year 1)

Serious events: 680 serious events

Other events: 0 other events

Deaths: 0 deaths

Fluzone® Vaccine (Year 1)

Serious events: 704 serious events

Other events: 0 other events

Deaths: 0 deaths

Fluzone® High Dose Vaccine (Year 2)

Serious events: 643 serious events

Other events: 0 other events

Deaths: 0 deaths

Fluzone® Vaccine (Year 2)

Serious events: 738 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	Fluzone® High Dose Vaccine (Year 1) n=7254 participants at risk Adults ≥65 years of age received one dose of Fluzone High Dose vaccine	Fluzone® Vaccine (Year 1) n=7243 participants at risk Adults ≥65 years of age received one dose of Fluzone vaccine	Fluzone® High Dose Vaccine (Year 2) n=8738 participants at risk Adults ≥65 years of age received one dose of Fluzone High Dose vaccine	Fluzone® Vaccine (Year 2) n=8748 participants at risk Adults ≥65 years of age received one dose of Fluzone vaccine
Gastrointestinal disorders Rectal haemorrhage	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.06% 4/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.06% 5/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Retroperitoneal haematoma	0.03% 2/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Small intestinal obstruction	0.07% 5/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.14% 10/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.05% 4/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 3/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Spigelian hernia	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Tongue oedema	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Umbilical hernia, obstructive	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Bronchial carcinoma	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Chronic lymphocytic leukaemia	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Colon adenoma	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Colon cancer	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.04% 3/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.05% 4/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.06% 5/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Heart valve incompetence	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Ischaemic cardiomyopathy	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Blood and lymphatic system disorders Anaemia	0.11% 8/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.06% 4/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.10% 9/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.08% 7/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Blood and lymphatic system disorders Anaemia macrocytic	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Blood and lymphatic system disorders Anaemia of chronic disease	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Blood and lymphatic system disorders Bone marrow failure	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Blood and lymphatic system disorders Coagulopathy	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Blood and lymphatic system disorders Haemorrhagic anaemia	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.04% 3/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Blood and lymphatic system disorders Idiopathic thrombocytopenic purpura	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Blood and lymphatic system disorders Iron deficiency anaemia	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Blood and lymphatic system disorders Leukocytosis	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Blood and lymphatic system disorders Microcytic anaemia	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Blood and lymphatic system disorders Splenic lesion	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Blood and lymphatic system disorders Thrombocytopenia	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Acute coronary syndrome	0.06% 4/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 3/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Acute myocardial infarction	0.03% 2/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.10% 7/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.13% 11/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.10% 9/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Angina pectoris	0.03% 2/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.11% 8/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.06% 5/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.06% 5/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Angina unstable	0.03% 2/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.12% 9/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.09% 8/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.06% 5/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Aortic valve disease mixed	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Aortic valve stenosis	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Arrhythmia	0.06% 4/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Arteriosclerosis coronary artery	0.03% 2/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Arteriospasm coronary	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Atrial fibrillation	0.39% 28/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.40% 29/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.26% 23/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.43% 38/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Atrial flutter	0.04% 3/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.05% 4/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Atrial tachycardia	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Atrial thrombosis	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Atrioventricular block	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Atrioventricular block complete	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Atrioventricular block second degree	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Bradyarrhythmia	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Bradycardia	0.07% 5/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.06% 4/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Bundle branch block left	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Cardiac arrest	0.08% 6/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.06% 5/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Cardiac disorder	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Cardiac failure	0.03% 2/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.05% 4/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Cardiac failure acute	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Cardiac failure chronic	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Cardiac failure congestive	0.21% 15/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.30% 22/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.22% 19/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.33% 29/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Cardiac valve disease	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Cardio-respiratory arrest	0.04% 3/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Cardiomegaly	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Cardiomyopathy	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 3/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Cardiopulmonary failure	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Cardiovascular disorder	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Congestive cardiomyopathy	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Coronary artery disease	0.19% 14/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.25% 18/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.18% 16/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.21% 18/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Coronary artery insufficiency	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Coronary artery occlusion	0.06% 4/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 3/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Coronary artery stenosis	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Mitral valve disease	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Mitral valve incompetence	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Mitral valve stenosis	0.03% 2/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Myocardial infarction	0.29% 21/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.29% 21/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.16% 14/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.11% 10/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Proctitis	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Myocardial ischaemia	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Palpitations	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Pericardial effusion	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Pericarditis	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Sick sinus syndrome	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 3/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.05% 4/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Sinus arrhythmia	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Sinus bradycardia	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Stress cardiomyopathy	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Supraventricular tachycardia	0.04% 3/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.04% 3/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 3/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Tachycardia	0.03% 2/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Ventricular extrasystoles	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Ventricular fibrillation	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Cardiac disorders Ventricular tachycardia	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Congenital, familial and genetic disorders Arteriovenous malformation	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Congenital, familial and genetic disorders Gastrointestinal arteriovenous malformation	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Ear and labyrinth disorders Vertigo	0.03% 2/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.07% 5/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.08% 7/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Endocrine disorders Adrenocortical insufficiency acute	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Endocrine disorders Goitre	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Endocrine disorders Hyperparathyroidism	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Endocrine disorders Hyperthyroidism	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Endocrine disorders Thyroid mass	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Eye disorders Cataract	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Eye disorders Periorbital oedema	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Eye disorders Retinal artery occlusion	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Eye disorders Retinal detachment	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Abdominal hernia	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 3/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Abdominal mass	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Abdominal pain	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.04% 3/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.06% 5/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.05% 4/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Abdominal pain lower	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Abdominal pain upper	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Abdominal wall haematoma	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Abdominal wall haemorrhage	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Alcoholic pancreatitis	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Anal fistula	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Colitis	0.03% 2/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.08% 6/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Colitis ischaemic	0.03% 2/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 3/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.05% 4/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Colonic polyp	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Colonic stenosis	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Constipation	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 3/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Crohn's disease	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Diaphragmatic hernia	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Diarrhoea	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Dieulafoy's vascular malformation	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Diverticular perforation	0.03% 2/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Diverticulum	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.07% 5/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Diverticulum intestinal	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Diverticulum intestinal haemorrhagic	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Duodenal stenosis	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Duodenal ulcer	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Duodenal ulcer haemorrhage	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Dysphagia	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Erosive oesophagitis	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Faecaloma	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Food poisoning	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Gastric antral vascular ectasia	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Gastric ulcer	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Gastric ulcer haemorrhage	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 3/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Gastritis	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.06% 4/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Gastritis erosive	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Gastroduodenitis	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Gastrointestinal disorder	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Gastrointestinal haemorrhage	0.08% 6/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.10% 7/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.06% 5/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.10% 9/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Gastrooesophageal reflux disease	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Gastrooesophagitis	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Haematemesis	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Haematochezia	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Haemorrhagic erosive gastritis	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Hiatus hernia	0.03% 2/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Ileus	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Impaired gastric emptying	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Inguinal hernia	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.05% 4/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Intestinal ischaemia	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Intestinal obstruction	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 3/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 3/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Intestinal perforation	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Intestinal polyp haemorrhage	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Large intestine perforation	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Lower gastrointestinal haemorrhage	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Lumbar hernia	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Mallory-Weiss syndrome	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Nausea	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Obstruction gastric	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Oesophageal obstruction	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Oesophageal spasm	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Oesophageal varices haemorrhage	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Pancreatitis	0.07% 5/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Pancreatitis acute	0.04% 3/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.06% 5/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Pancreatitis necrotising	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Pancreatitis relapsing	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Peptic ulcer	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Peptic ulcer haemorrhage	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Pharyngoesophageal diverticulum	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Upper gastrointestinal haemorrhage	0.06% 4/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.04% 3/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Volvulus	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Gastrointestinal disorders Vomiting	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
General disorders Adverse drug reaction	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
General disorders Asthenia	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
General disorders Chest discomfort	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
General disorders Chest pain	0.58% 42/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.37% 27/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.21% 18/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.18% 16/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
General disorders Death	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.04% 3/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
General disorders Device dislocation	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
General disorders Device failure	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
General disorders Device lead damage	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
General disorders Device malfunction	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
General disorders Device occlusion	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
General disorders Fatigue	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
General disorders Genaralized oedema	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Kidney infection	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
General disorders Hernia	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
General disorders Hernia obstructive	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
General disorders Impaired healing	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Laryngitis	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
General disorders Implant site inflammation	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
General disorders Influenza like illness	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
General disorders Ischaemic ulcer	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
General disorders Non-cardiac chest pain	0.08% 6/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.04% 3/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.05% 4/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
General disorders Oedema peripheral	0.03% 2/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
General disorders Pelvic mass	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
General disorders Pneumatosis	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
General disorders Pyrexia	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
General disorders Sudden cardiac death	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
General disorders Surgical failure	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Hepatobiliary disorders Bile duct obstruction	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Hepatobiliary disorders Cholangitis	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Hepatobiliary disorders Cholangitis acute	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Hepatobiliary disorders Cholecystitis	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.04% 3/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.09% 8/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 3/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Hepatobiliary disorders Cholecystitis acute	0.04% 3/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 3/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.05% 4/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Hepatobiliary disorders Cholecystitis chronic	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Hepatobiliary disorders Cholelithiasis	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.10% 7/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.06% 5/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Hepatobiliary disorders Chronic hepatic failure	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Hepatobiliary disorders Gallbladder pain	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Hepatobiliary disorders Gallbladder perforation	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Hepatobiliary disorders Hepatitis	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Hepatobiliary disorders Hepatorenal syndrome	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Immune system disorders Drug hypersensitivity	0.03% 2/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Immune system disorders Hypersensitivity	0.03% 2/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Abdominal abscess	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Abdominal sepsis	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Abdominal wall abscess	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Abscess	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Abscess limb	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Acute sinusitis	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Appendicitis	0.03% 2/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.06% 4/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 3/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.05% 4/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Arthritis bacterial	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Arthritis infective	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Atypical myocobacterial pneumonia	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Bronchitis	0.07% 5/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.06% 4/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.10% 9/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.06% 5/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Bronchopneumonia	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Bursitis infective	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Cellulitis	0.17% 12/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.12% 9/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.09% 8/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.14% 12/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Cholecystitis infective	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Clostridium difficile colitis	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.04% 3/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Cystitis	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Device related infection	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Diabetic foot infection	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Diabetic gangrene	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Diverticulitis	0.11% 8/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.07% 5/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.06% 5/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.13% 11/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Endocarditis bacterial	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Enterocolitis infectious	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Enterocolitis viral	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Escherichia bacteraemia	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Escherichia urinary tract infection	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Gangrene	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Gastric ulcer helicobacter	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Gastroenteritis	0.07% 5/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.08% 6/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.06% 5/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.10% 9/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Gastroenteritis bacterial	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Gastroenteritis salmonella	0.03% 2/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Gastroenteritis viral	0.03% 2/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Gastrointestinal infection	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Groin infection	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Herpes zoster	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Infected cyst	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Infective exacerbation of bronchiectasis	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Influenza	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 3/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.07% 6/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Liver abscess	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Lobar pneumonia	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.07% 6/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Localised infection	0.03% 2/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Lung infection	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Nocardiosis	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Osteomyelitis	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Tibia fracture	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Peridiverticular abscess	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Perineal abscess	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Periorbital cellulitis	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Perirectal abscess	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Peritonitis	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Pneumonia	0.39% 28/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.61% 44/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.40% 35/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.50% 44/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Pneumonia bacterial	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Pneumonia pneumococcal	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Pneumonia primary atypical	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Pneumonia staphylococcal	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Pneumonia viral	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Postoperative wound infection	0.03% 2/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Pseudomonas infection	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Pyelonephritis	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.04% 3/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 3/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Pyelonephritis acute	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Respiratory syncytial virus infection	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Sepsis	0.06% 4/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.04% 3/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.06% 5/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.06% 5/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Septic shock	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Sinusitis	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Staphylococcal infection	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 3/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Tracheobronchitis	0.03% 2/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Upper respiratory tract infection	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Urethritis	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Urinary tract infection	0.12% 9/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.11% 8/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.06% 5/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.18% 16/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Urosepsis	0.07% 5/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.04% 3/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.05% 4/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Vestibular neuronitis	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Viral diarrhoea	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Viral infection	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.05% 4/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Viral labyrinthitis	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Viral pericarditis	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Clostridial infection	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Accident	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Accidental overdose	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Alcohol poisoning	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Ankle fracture	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.07% 5/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.06% 5/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 3/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Arteriovenous fistula site complication	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Burns second degree	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Carbon monoxide poisoning	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Cervical vertebral fracture	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Compression fracture	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Breast cancer stage I	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Concussion	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Contusion	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 3/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Craniocerebral injury	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Ear injury	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Fall	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.05% 4/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Femoral neck fracture	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.07% 5/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Femur fracture	0.08% 6/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.07% 5/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Foot fracture	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Forearm fracture	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Fractured sacrum	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Gastrointestinal stoma complication	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Graft complication	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Graft thrombosis	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Head injury	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Hip fracture	0.11% 8/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.06% 4/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.06% 5/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.13% 11/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Humerus fracture	0.04% 3/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.05% 4/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Incisional hernia	0.03% 2/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Injury	0.03% 2/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Intentional overdose	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Joint dislocation	0.03% 2/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 3/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Joint injury	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Joint sprain	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Laceration	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Ligament sprain	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Meniscus lesion	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Multiple fractures	0.04% 3/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.04% 3/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Multiple injuries	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Open fracture	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Patella fracture	0.03% 2/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Pelvic fracture	0.04% 3/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 3/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Periprosthetic fracture	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Post laminectomy syndrome	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Post procedural complication	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Post procedural haemorrhage	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Postoperative fever	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Postoperative respiratory distress	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Procedural pain	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Pubis fracture	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Radius fracture	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Respiratory fume inhalation disorder	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Rib fracture	0.03% 2/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.04% 3/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 3/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Road traffic accident	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 3/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Skull fracture	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Skull fractured base	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Spinal compression fracture	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Spinal fracture	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Splenic rupture	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Sternal fracture	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Subdural haematoma	0.07% 5/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.04% 3/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Tendon rupture	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Toxicity to various agents	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Traumatic fracture	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Upper limb fracture	0.03% 2/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Vascular graft complication	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Wound	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Wound dehiscence	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Wrist fracture	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 3/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Investigations Blood pressure increased	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Investigations Cardiac stress test abnormal	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Investigations Prostatic specific antigen increased	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Metabolism and nutrition disorders Dehydration	0.04% 3/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.06% 4/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.05% 4/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.06% 5/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Metabolism and nutrition disorders Diabetic ketoacidosis	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Metabolism and nutrition disorders Diabetes mellitus inadequate control	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Metabolism and nutrition disorders Failure to thrive	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Metabolism and nutrition disorders Fluid overload	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Metabolism and nutrition disorders Fluid retention	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Metabolism and nutrition disorders Gout	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Metabolism and nutrition disorders Hypercalcaemia	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Metabolism and nutrition disorders Hyperglycaemia	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Metabolism and nutrition disorders Hypoglycaemia	0.03% 2/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.04% 3/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.06% 5/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Metabolism and nutrition disorders Hypokalaemia	0.04% 3/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Metabolism and nutrition disorders Hyponatraemia	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 3/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 3/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Metabolism and nutrition disorders Malnutrition	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Metabolism and nutrition disorders Type 2 diabetes mellitus	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Musculoskeletal and connective tissue disorders Arthralgia	0.08% 6/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.06% 4/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.07% 6/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Musculoskeletal and connective tissue disorders Arthritis	0.06% 4/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.05% 4/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Musculoskeletal and connective tissue disorders Arthropathy	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Musculoskeletal and connective tissue disorders Back pain	0.06% 4/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.07% 6/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Musculoskeletal and connective tissue disorders Bursitis	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Metabolism and nutrition disorders Hypocalcaemia	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Musculoskeletal and connective tissue disorders Cervical spinal stenosis	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.04% 3/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.06% 5/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Musculoskeletal and connective tissue disorders Chondrocalcinosis pyrophosphate	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Musculoskeletal and connective tissue disorders Costochondritis	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Musculoskeletal and connective tissue disorders Exostosis	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Musculoskeletal and connective tissue disorders Foot deformity	0.03% 2/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Respiratory, thoracic and mediastinal disorders Respiratory failure	0.07% 5/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.07% 5/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.05% 4/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.06% 5/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Musculoskeletal and connective tissue disorders Fracture malunion	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Musculoskeletal and connective tissue disorders Gouty tophus	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Musculoskeletal and connective tissue disorders Groin pain	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 3/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Musculoskeletal and connective tissue disorders Intervertebral disc degeneration	0.04% 3/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Musculoskeletal and connective tissue disorders Intervertebral disc displacement	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Musculoskeletal and connective tissue disorders Intervertebral disc protrusion	0.03% 2/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.07% 5/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Musculoskeletal and connective tissue disorders Knee deformity	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Musculoskeletal and connective tissue disorders Kyphosis	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Musculoskeletal and connective tissue disorders Lumbar spinal stenosis	0.08% 6/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.10% 7/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.08% 7/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.05% 4/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Musculoskeletal and connective tissue disorders Monarthritis	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Musculoskeletal and connective tissue disorders Muscle atrophy	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Musculoskeletal and connective tissue disorders Muscle spasms	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Musculoskeletal and connective tissue disorders Muscular weakness	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Musculoskeletal and connective tissue disorders Musculoskeletal chest pain	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 3/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Musculoskeletal and connective tissue disorders Musculoskeletal pain	0.04% 3/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Musculoskeletal and connective tissue disorders Neck pain	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.04% 3/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Musculoskeletal and connective tissue disorders Osteoarthritis	0.66% 48/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.40% 29/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.57% 50/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.40% 35/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Musculoskeletal and connective tissue disorders Osteonecrosis	0.03% 2/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Musculoskeletal and connective tissue disorders Osteoporosis	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Musculoskeletal and connective tissue disorders Osteoporotic fracture	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Musculoskeletal and connective tissue disorders Pain in extremity	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Musculoskeletal and connective tissue disorders Periarthritis	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Musculoskeletal and connective tissue disorders Polymyalgia rheumatica	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Musculoskeletal and connective tissue disorders Rhabdomyolysis	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Musculoskeletal and connective tissue disorders Rheumatoid arthritis	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Musculoskeletal and connective tissue disorders Rotator cuff syndrome	0.04% 3/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Musculoskeletal and connective tissue disorders Spinal column stenosis	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.05% 4/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Musculoskeletal and connective tissue disorders Spinal osteoarthritis	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Musculoskeletal and connective tissue disorders Spondylolisthesis	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.05% 4/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Musculoskeletal and connective tissue disorders Synovial cyst	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Acute leukaemia	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Acute myeloid leukaemia	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Acute promyelocytic leukaemia	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Adenocarcinoma	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Adenocarcinoma pancreas	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Adenoid cystic carcinoma	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) B-cell small lymphocytic lymphoma	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Basal cell carcinoma	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Benign neoplasm	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Benign renal neoplasm	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Bile duct cancer	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Bladder cancer	0.07% 5/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.04% 3/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 3/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Bladder cancer recurrent	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Bladder neoplasm	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Bladder transitional cell carcinoma	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Bone cancer metastatic	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Bone neoplasm	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Bone neoplasm malignant	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Brain neoplasm	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Brain neoplasm malignant	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Breast cancer	0.10% 7/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.15% 11/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.08% 7/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.08% 7/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Breast cancer in situ	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Breast cancer metastatic	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Breast cancer recurrent	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Colon cancer metastatic	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Colon cancer stage II	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Colorectal cancer	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Duodenal neoplasm	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Endometrial cancer	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Endometrial cancer stage II	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Gastric cancer	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Gastric cancer recurrent	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Gastric cancer stage I	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Gastrinoma	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Gastrointestinal stromal tumour	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Glottis carcinoma	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Head and neck cancer	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Hepatic cancer metastatic	0.03% 2/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Hepatic neoplasm malignant	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Hodgkin's disease	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Intracranial meningioma malignant	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Laryngeal cancer	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Laryngeal cancer stage I	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lentigo maligna stage unspecified	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Leukaemia	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Liposarcoma	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung adenocarcinoma	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung cancer metastatic	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung carcinoma cell type unspecified stage I	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung carcinoma cell type unspecified stage 0	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung neoplasm	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung neoplasm malignant	0.06% 4/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.15% 11/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.07% 6/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 3/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung squamous cell carcinoma stage unspecified	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lymphoma	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Malignant melanoma	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Meningioma	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Meningioma benign	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Metastases to bone	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Metastases to central nervous system	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Metastases to lung	0.03% 2/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Metastatic carcinoid tumour	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Metastatic malignant melanoma	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Metastatic neoplasm	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Metastatic squamous cell carcinoma	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Multiple myeloma	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Myelodysplastic syndrome	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Myeloid leukaemia	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Myeloma recurrence	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Neoplasm malignant	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Neuroendocrine tumour	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Non-Hodgkin's lymphoma	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Non-small cell lung cancer	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Non-small cell lung cancer metastatic	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Oesophageal adenocarcinoma	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Oesophageal carcinoma	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Ovarian cancer metastatic	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Pancreatic carcinoma	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.04% 3/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Pancreatic carcinoma metastatic	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Paraproteinaemia	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Penis carcinoma	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Pituitary tumour	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Pituitary tumour benign	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Pleural neoplasm	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Prostate cancer	0.12% 9/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 3/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.05% 4/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Prostate cancer metastatic	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Rectal cancer	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.04% 3/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Renal cancer	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Renal cell carcinoma	0.04% 3/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Retroperitoneal neoplasm	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Salivary gland cancer	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Sarcoma	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Skin cancer	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Small cell lung cancer extensive stage	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Small cell lung cancer stage unspecified	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Small intestine carcinoma	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Squamous cell carcinoma	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.07% 5/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Squamous cell carcinoma of skin	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Throat cancer	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Thyroid cancer	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.06% 4/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Thyroid neoplasm	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tongue neoplasm malignant stage unspecified	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tonsil cancer	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Transitional cell carcinoma	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Uterine cancer	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 3/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Acute disseminated encephalomyelitis	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Amnesia	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Ataxia	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Autonomic nervous system imbalance	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Basal ganglia infarction	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Carotid artery occlusion	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Carotid artery stenosis	0.04% 3/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.05% 4/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Cerebral amyloid angiopathy	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Cerebral cyst	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Cerebral haemorrhage	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Cerebral infarction	0.03% 2/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Cerebral Ischaemia	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Cerebrovascular accident	0.28% 20/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.26% 19/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.15% 13/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.24% 21/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Cervicobrachial syndrome	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Cervical myelopathy	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Cognitive disorder	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Complex partial seizures	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Malignant melanoma in situ	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Convulsion	0.04% 3/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.04% 3/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Dementia Alzheimer's type	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Dementia with Lewy bodies	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Depressed level of consciousness	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Dizziness	0.03% 2/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Dizziness postural	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Dyskinesia	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Encephalopathy	0.03% 2/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Epilepsy	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Guillain-Barre syndrome	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Haemorrhage intracranial	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Haemorrhagic stroke	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Headache	0.03% 2/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Hemiparesis	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Hydrocephalus	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Hypertensive encephalopathy	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Intracranial aneurysm	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Intraventricular haemorrhage	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Ischaemic stroke	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Lacunar infarction	0.03% 2/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Lethargy	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Loss of consciousness	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Lumbar radiculopathy	0.04% 3/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Metabolic encephalopathy	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Migraine	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Myasthenia gravis	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Myelopathy	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Normal pressure hydrocephalus	0.04% 3/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Paraesthesia	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Parkinson's disease	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Presyncope	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.04% 3/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 3/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Radiculopathy	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Sciatica	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Spondylitic myelopathy	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Subarachnoid haemorrhage	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.06% 4/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Syncope	0.25% 18/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.26% 19/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.17% 15/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.18% 16/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Thrombotic cerebral infarction	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Toxic encephalopathy	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Transient global amnesia	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Transient ischaemic attack	0.17% 12/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.21% 15/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.10% 9/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.14% 12/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders VIIth nerve paralysis	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 3/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders VIth nerve paralysis	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Psychiatric disorders Affective disorder	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Psychiatric disorders Alcohol withdrawal syndrome	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Psychiatric disorders Bipolar disorder	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Psychiatric disorders Bipolar I disorder	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Psychiatric disorders Completed suicide	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Psychiatric disorders Delirium	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Psychiatric disorders Depression	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Psychiatric disorders Hallucination, visual	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Psychiatric disorders Major depression	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Psychiatric disorders Mental status changes	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.06% 5/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.05% 4/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Psychiatric disorders Panic attack	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Psychiatric disorders Psychotic disorder	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Psychiatric disorders Suicidal ideation	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Renal and urinary disorders Bladder fibrosis	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Renal and urinary disorders Bladder prolapse	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Renal and urinary disorders Calculus bladder	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Renal and urinary disorders Calculus ureteric	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Renal and urinary disorders Calculus urinary	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Renal and urinary disorders Dysuria	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Renal and urinary disorders Haematuria	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Renal and urinary disorders Hydronephrosis	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Renal and urinary disorders Nephrolithiasis	0.04% 3/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.07% 5/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Renal and urinary disorders Obstructive uropathy	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Renal and urinary disorders Renal artery stenosis	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Renal and urinary disorders Renal colic	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Renal and urinary disorders Renal failure	0.03% 2/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.05% 4/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Renal and urinary disorders Renal failure acute	0.11% 8/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.07% 5/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.13% 11/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.16% 14/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Renal and urinary disorders Renal failure chronic	0.06% 4/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 3/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Renal and urinary disorders Renal mass	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Renal and urinary disorders Stress urinary incontinence	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Renal and urinary disorders Urethral stenosis	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Renal and urinary disorders Urinary incontinence	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Renal and urinary disorders Urinary retention	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Reproductive system and breast disorders Benign prostatic hyperplasia	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.04% 3/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Reproductive system and breast disorders Cystocele	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Reproductive system and breast disorders Endometrial hyperplasia	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Reproductive system and breast disorders Erectile dysfunction	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Reproductive system and breast disorders Genital prolapse	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Reproductive system and breast disorders Ovarian cyst	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Reproductive system and breast disorders Ovarian mass	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Reproductive system and breast disorders Pelvic pain	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Reproductive system and breast disorders Pelvic prolapse	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Reproductive system and breast disorders Prostatitis	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Reproductive system and breast disorders Prostatomegaly	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Reproductive system and breast disorders Uterine prolapse	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Reproductive system and breast disorders Uterovaginal prolapse	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Reproductive system and breast disorders Vaginal haematoma	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Respiratory, thoracic and mediastinal disorders Acute respiratory failure	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.08% 6/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.07% 6/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.08% 7/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Respiratory, thoracic and mediastinal disorders Alveolitis allergic	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Respiratory, thoracic and mediastinal disorders Asthma	0.06% 4/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 3/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.06% 5/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Respiratory, thoracic and mediastinal disorders Bronchitis chronic	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Respiratory, thoracic and mediastinal disorders Chronic obstructive pulmonary disease	0.29% 21/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.18% 13/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.17% 15/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.41% 36/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Respiratory, thoracic and mediastinal disorders Chronic respiratory failure	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.07% 5/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.08% 6/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 3/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.09% 8/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Respiratory, thoracic and mediastinal disorders Dyspnoea exertional	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Respiratory, thoracic and mediastinal disorders Emphysema	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Respiratory, thoracic and mediastinal disorders Eosinophilic pneumonia	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Respiratory, thoracic and mediastinal disorders Epistaxis	0.04% 3/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Respiratory, thoracic and mediastinal disorders Haemoptysis	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Respiratory, thoracic and mediastinal disorders Haemothorax	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Respiratory, thoracic and mediastinal disorders Hypoxia	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Respiratory, thoracic and mediastinal disorders Interstitial lung disease	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Respiratory, thoracic and mediastinal disorders Nasal septum deviation	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Respiratory, thoracic and mediastinal disorders Pleural haemorrhage	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Respiratory, thoracic and mediastinal disorders Pleurisy	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Respiratory, thoracic and mediastinal disorders Pleuritic pain	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Respiratory, thoracic and mediastinal disorders Pneumonia aspiration	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.04% 3/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Respiratory, thoracic and mediastinal disorders Pneumonitis	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Respiratory, thoracic and mediastinal disorders Pneumothorax	0.03% 2/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.05% 4/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.07% 5/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.10% 7/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.07% 6/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.15% 13/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Respiratory, thoracic and mediastinal disorders Pulmonary fibrosis	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Respiratory, thoracic and mediastinal disorders Pulmonary hypertension	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Respiratory, thoracic and mediastinal disorders Pulmonary oedema	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Respiratory, thoracic and mediastinal disorders Respiratory arrest	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Respiratory, thoracic and mediastinal disorders Sleep apnoea syndrome	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Skin and subcutaneous tissue disorders Angioedema	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Skin and subcutaneous tissue disorders Capillaritis	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Skin and subcutaneous tissue disorders Decubitus ulcer	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Skin and subcutaneous tissue disorders Diabetic foot	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Skin and subcutaneous tissue disorders Hypoaesthesia facial	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Skin and subcutaneous tissue disorders Panniculitis	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Skin and subcutaneous tissue disorders Rash	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Skin and subcutaneous tissue disorders Stevens-Johnson syndrome	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Skin and subcutaneous tissue disorders Skin hypertrophy	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Social circumstances Activities of daily living impaired	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Surgical and medical procedures Colostomy	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Surgical and medical procedures Face lift	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Surgical and medical procedures Implantable defibrillator removal	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Surgical and medical procedures Intraocular lens implant	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Surgical and medical procedures Renal surgery	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Surgical and medical procedures Surgery	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Vascular disorders Accelerated hypertension	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Vascular disorders Aneurysm ruptured	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Vascular disorders Aortic aneurysm	0.07% 5/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.04% 3/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.06% 5/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.07% 6/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Vascular disorders Aortic aneurysm rupture	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Vascular disorders Aortic dissection	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Vascular disorders Aortic rupture	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Vascular disorders Aortic stenosis	0.03% 2/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Vascular disorders Arterial occlusive disease	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Vascular disorders Arterial stenosis limb	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Vascular disorders Arterial thrombosis limb	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Vascular disorders Arteriosclerosis	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 3/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Vascular disorders Arteriovenous fistula	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Vascular disorders Deep vein thrombosis	0.07% 5/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.07% 5/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.07% 6/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Vascular disorders Embolism venous	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Vascular disorders Femoral artery occlusion	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Vascular disorders Haematoma	0.06% 4/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 2/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Vascular disorders Hypertension	0.11% 8/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.06% 4/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.05% 4/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 3/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Vascular disorders Hypertensive crisis	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Vascular disorders Hypertensive emergency	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Vascular disorders Hypotension	0.11% 8/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.06% 4/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Vascular disorders Hypovolaemic shock	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Vascular disorders Infarction	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Vascular disorders Intermittent claudication	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Vascular disorders Intra-abdominal haematoma	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Vascular disorders Ischaemia	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Vascular disorders Malignant hypertension	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Vascular disorders Orthostatic hypertension	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Vascular disorders Orthostatic hypotension	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.07% 5/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Vascular disorders Peripheral arterial occlusive disease	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Vascular disorders Peripheral artery aneurysm	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Vascular disorders Peripheral ischaemia	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.03% 3/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Vascular disorders Peripheral vascular disorder	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.02% 2/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Vascular disorders Shock	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Vascular disorders Steal syndrome	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Vascular disorders Thrombosis	0.01% 1/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Vascular disorders Venous insufficiency	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Bacteraemia	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Bacterial infection	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Injury, poisoning and procedural complications Extradural haematoma	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Nervous system disorders Basal ganglia haemorrhage	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Urinary tract infection bacterial	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.
Infections and infestations Appendicitis perforated	0.00% 0/7254 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/7243 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.00% 0/8738 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.	0.01% 1/8748 • All serious adverse events, including deaths and adverse events (AEs) of special interest were collected from Day 0 (post-vaccination) up to Day 240 post-vaccination. The total number (N) data for the serious adverse events were presented for each study year according to the study vaccine actually recieved by the participants - the Full (as treated) Analysis Set.

Other adverse events

Adverse event data not reported

Additional Information

Medical Director

Sanofi Pasteur Inc.

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place